August 3, 2006—A recent ruling that gives terminally ill patients the right to use experimental treatments could hamper the Food and Drug Administration’s ability to evaluate drugs, according to an article in today’s issue of the New England Journal of Medicine. The decision, by an advisory panel of the U.S. Court of Appeals, now goes to the full court for review.